PARKINSON'S DISEASE NEWS

28th May 2011 - News release

NLX-P101 CLINICAL TRIAL DATA FOR PARKINSON'S DISEASE

Neurologix have provided details of a Phase 2 clinical trial of NLX-P101 in Parkinson's Disease. NLX-P101 is a gene therapy under investigation for the treatment of Parkinson's Disease. NLX-P101 increases the level of GABA, a substance involved in muscular movement that is naturally produced in the brain.  In a one-year follow-up, patients treated with NLX-P101 who achieved clinically-meaningful symptom improvements increased from 50% at six months to 63% after one year. No serious adverse events related to the therapy or surgical procedure were reported.

NLX-P101 led to an average improvement of 23% in those people treated, which is an 8 point reduction from their symptom questionnaire score. Those patients undergoing sham surgery (those that were untreated) had an average improvement of nearly 13%, which is nearly a 5 point reduction from their symptom questionnaire score.  Therefore the average improvement beyond that of doing nothing was only actually 10% and occurred in only just over half of patients. For more information go to the News release. For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports